Captopril: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
David Canner (talk | contribs)
7,699 edits
No edit summary
David Canner (talk | contribs)
7,699 edits
No edit summary
Line 14: Line 14:
{| class="wikitable" border="1" width="50%" style="text-align:center"
{| class="wikitable" border="1" width="50%" style="text-align:center"
|-
|-
!  colspan="8" align="center"| ACE-Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] Comparison at Equivalent Dosages <ref>PMID: 7867683</ref> <ref>DOI: 10.1111/j.1365-2710.2005.00646.x</ref> <ref>PMID: 15985045</ref>
!  colspan="8" align="center"| ACE-Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] Comparison at Equivalent Dosages <ref>PMID: 7867683</ref> <ref>DOI: 10.1111/j.1365-2710.2005.00646.x</ref> <ref>PMID: 15985045</ref><ref>PMID: 16075412</ref> <ref>PMID:7527101</ref> <ref>ISBN:0471752158</ref>
|-
|-
! Parameter
! Parameter
Line 30: Line 30:
! .67
! .67
! 1.06
! 1.06
!
! .5
!
! .75
!
! .72
|-
|-
! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml)  
! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml)  
Line 39: Line 39:
! 16.4
! 16.4
! 314
! 314
!
! 149
!
! 105
!
! 1.68
|-
|-
! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%)
! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%)
Line 49: Line 49:
!
!
!
!
!
!75
!
!
|-
|-
Line 66: Line 66:
! 1.93
! 1.93
! 1.6
! 1.6
!
! 10
!
! .9
!
! .68
|-
|-
! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
Line 75: Line 75:
! 21.9
! 21.9
! 450
! 450
!
! 140
!
! 182
!
! 1.86
|-
|-
! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM)
! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM)
! 1.1
! 1.1
! 5.5
! 5.5
! [[Ramipril]]
! 5.0
! 5.4
! 5.4
! [[Benazepril]]
! 1.7
! [[Perindopril]]
! 2.4
! [[Trandolapril]]
! 2.5
|-
|-
! Equivalent Dosage (mg)
! Dosage (mg)
! 10
! 10
! 20
! 20
Line 94: Line 94:
!
!
!
!
!
!  
!
! 2
|-
|-
! Metabolism
! Metabolism
Line 109: Line 109:
==References==
==References==
<references/>
<references/>
__NOEDITSECTION__
__NOTOC__

Revision as of 19:00, 28 November 2010

Captopril, also known as Capoten

Drag the structure with the mouse to rotate

Better Known as: Capoten

  • Marketed By: Bristol-Myers Squibb
  • Major Indication: Hypertension & Congestive Heart Failure
  • Drug Class: ACE Inhibitor
  • Date of FDA Approval (Patent Expiration): 1981 (1996)
  • 2009 Sales: N/A
  • Why You Should Care: It was the first Angiotensin-Converting Enzyme Inhibitor. Was one of the earliest successes of Structure-Based drug design.
  • The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information

Mechanism of Action

Extensive research has validated a pathological role for Angiotensin II in cardiac, renal and vascular diseases. [1] Bradykinin, a small peptide that counterbalance the effects of Angiotensin II by acting as a strong vasodilator upon binding AT2, is degraded by the same ACE-1 enzyme. Since ACE-1 is the primary producer of Angiotensin II and primary degrader of Bradykinins, inhibition of ACE-1 has proven an effective treatment for Hypertension and Congestive Heart Failure. Captopril binds to the ACE-1 binding site of Angiotensin-Converting enzyme, preventing ACE-1 from binding angiotensin. Captopril, binds ACE-1 precisely, forming electrostatic interactions with His 353, Glu 384, Lys 511, His 513 and Tyr 520, along with zinc cation. [2]

Pharmacokinetics

ACE-Inhibitor Pharmacokinetics Comparison at Equivalent Dosages [3] [4] [5][6] [7] [8]
Parameter Captopril Lisinopril Ramipril Enalapril Benazepril Perindopril Trandolapril
Tmax (hr) .98 6.5 .67 1.06 .5 .75 .72
Cmax (ng/ml) 1210 79800 16.4 314 149 105 1.68
Bioavailability (%) 72 75
Protein Binding (%) 96.7
T1/2 (hr) .56 10.1 1.93 1.6 10 .9 .68
AUC (ng/ml/hr) 1673 1016000 21.9 450 140 182 1.86
IC50 (nM) 1.1 5.5 5.0 5.4 1.7 2.4 2.5
Dosage (mg) 10 20 2
Metabolism

References

  1. ↑ Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst. 2006 Mar;7(1):3-14. PMID:17083068
  2. ↑ Natesh R, Schwager SL, Evans HR, Sturrock ED, Acharya KR. Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry. 2004 Jul 13;43(27):8718-24. PMID:15236580 doi:10.1021/bi049480n
  3. ↑ Sun JX, Cipriano A, Chan K, John VA. Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. Eur J Clin Pharmacol. 1994;47(3):285-9. PMID:7867683
  4. ↑ Arafat T, Awad R, Hamad M, Azzam R, Al-Nasan A, Jehanli A, Matalka K. Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. J Clin Pharm Ther. 2005 Aug;30(4):319-28. PMID:15985045 doi:10.1111/j.1365-2710.2005.00646.x
  5. ↑ Arafat T, Awad R, Hamad M, Azzam R, Al-Nasan A, Jehanli A, Matalka K. Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. J Clin Pharm Ther. 2005 Aug;30(4):319-28. PMID:15985045 doi:10.1111/j.1365-2710.2005.00646.x
  6. ↑ Tamimi JJ, Salem II, Alam SM, Zaman Q, Dham R. Bioequivalence evaluation of two brands of lisinopril tablets (Lisotec and Zestril) in healthy human volunteers. Biopharm Drug Dispos. 2005 Nov;26(8):335-9. PMID:16075412 doi:10.1002/bdd.465
  7. ↑ Arner P, Wade A, Engfeldt P, Mouren M, Stepniewski JP, Sultan E, Bryce T, Lenfant B. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to young and elderly patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol. 1994;23 Suppl 4:S44-9. PMID:7527101
  8. ↑ ISBN:0471752158


Proteopedia Page Contributors and Editors (what is this?)

David Canner, Alexander Berchansky

Retrieved from "https://proteopedia.org/index.php?title=Captopril&oldid=1149914"